Overview

Urokinase Therapy in Diabetic Foot Syndrome

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether a treatment with urokinase (500 000 or 1 000 000 IU) can lead to ulcer-healing, lower rate of major amputation, and prolonged survival in patients with diabetic foot syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
medac GmbH